Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Kanion Pharma Gains Control of a Fellow TCM Maker

publication date: Jun 22, 2010
Jiangsu Kanion Pharmaceutical will add an additional 33% stake in Jiangsu Nanxing Pharmaceutical to its existing 30% holding in the company, giving it 63% ownership and majority control. Kanion is buying the shares from Lianyungang Jiandian Technology for 81.4 million RMB ($12 million). Both companies are involved in producing TCM products. More details...

Stock Symbol: (SHEX: 600557)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital